Sentieon

Sentieon is a leading provider of high-performance, software-only bioinformatics solutions for genomic secondary analysis, serving research, clinical, and conservation clients. Its core technology offers drop-in, accelerated replacements for industry-standard tools like BWA-MEM and GATK, delivering significant improvements in speed (e.g., <30 minutes for a 30x whole genome) and cost-efficiency on generic CPU/ARM hardware. The company has established strong validation through customer publications and precisionFDA challenge wins, processing millions of samples for over 1,800 trusted clients. Sentieon operates as a private, revenue-generating platform company capitalizing on the growing computational demands of large-scale genomics.

A suite of highly optimized, CPU/ARM-accelerated bioinformatics software algorithms for genomic secondary analysis. It provides drop-in replacements for industry-standard tools (e.g., BWA-MEM, GATK) with identical or superior output, incorporating pre-trained, sequencing-platform-specific machine learning models for top accuracy. The platform is sequencer-agnostic and deployable on any generic hardware or cloud instance.

Sentieon competes primarily in the genomic secondary analysis acceleration market. Key competitors include open-source standards (GATK, BWA), commercial GPU-accelerated software like NVIDIA Clara Parabricks, and integrated cloud bioinformatics platforms from Google (Google Genomics), Amazon (Amazon Omics), and DNAnexus. Sentieon's differentiation lies in its CPU/ARM optimization, drop-in compatibility, award-winning accuracy, and hardware vendor agnosticism.